Abstract: There is provided a semiconductor device including: a first source and a first drain of a first-channel-type MISFET formed on a first semiconductor crystal layer, which are made of a compound having an atom constituting the first semiconductor crystal layer and a nickel atom, a compound having an atom constituting the first semiconductor crystal layer and a cobalt atom, or a compound having an atom constituting the first semiconductor crystal layer, a nickel atom, and a cobalt atom; and a second source and a second drain of a second-channel-type MISFET formed on a second semiconductor crystal layer, which are made of a compound having an atom constituting the second semiconductor crystal layer and a nickel atom, a compound having an atom constituting the second semiconductor crystal layer and a cobalt atom, or a compound having an atom constituting the second semiconductor crystal layer, a nickel atom, and a cobalt atom.

Abstract: A copper compound-carried titanium oxide photocatalyst which is excellent in a photocatalytic activity and a viral inactivation property and a production process for the same can be provided by a copper compound-carried titanium oxide photocatalyst comprising titanium oxide in which a content of rutile type titanium oxide is 50% by mole or more and a monovalent copper compound and a divalent copper compound which are carried on a surface of the titanium oxide described above and a production process for a copper compound-carried titanium oxide photocatalyst, comprising a step of carrying a monovalent copper compound and a divalent copper compound on a surface of titanium oxide in which a content of rutile type titanium oxide is 50% by mole or more.

Abstract: An object of the present invention is to provide an agent for treating or preventing vasospasm. An object of the present invention is to provide an agent for treating or preventing cerebral vasospasm as well as arterial vasospasm. Further, an object of the present invention is to provide an agent for treating or preventing cerebral ischemia and cerebral infarction. The above problems are solved by an agent for treating and preventing vasospasm, cerebral ischemia, or cerebral infarction, comprising trehalose as the active ingredient. It is possible, by using such a trehalose-comprising agent, to suppress phenomena such as contraction of blood vessel and thickening of tunica intima and tunica media and to prevent or treat vasospasm and vasospasm-dependent diseases.